Investigation of incidence and causes of acute vision loss during anti-vascular endothelial growth factor therapy for neovascular age-related macular degeneration during a 4-year follow-up.
Akira MachidaAkio OishiEiko TsuikiYuki MaekawaJunko KuriharaYuki HirataEriko MachidaTakashi KitaokaPublished in: Retina (Philadelphia, Pa.) (2023)
Approximately half of the patients with AMD experienced acute vision loss during a 4-year, despite continuous anti-VEGF treatment. Most patients recovered from vision losses temporarily; however, they experienced worse visual outcomes subsequently.
Keyphrases
- age related macular degeneration
- vascular endothelial growth factor
- liver failure
- end stage renal disease
- endothelial cells
- respiratory failure
- ejection fraction
- newly diagnosed
- chronic kidney disease
- drug induced
- aortic dissection
- type diabetes
- risk factors
- prognostic factors
- peritoneal dialysis
- hepatitis b virus
- insulin resistance
- replacement therapy
- mechanical ventilation